1. Home
  2. KELYA vs CAPR Comparison

KELYA vs CAPR Comparison

Compare KELYA & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KELYA
  • CAPR
  • Stock Information
  • Founded
  • KELYA 1946
  • CAPR 2005
  • Country
  • KELYA United States
  • CAPR United States
  • Employees
  • KELYA N/A
  • CAPR N/A
  • Industry
  • KELYA Professional Services
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • KELYA Consumer Discretionary
  • CAPR Health Care
  • Exchange
  • KELYA Nasdaq
  • CAPR Nasdaq
  • Market Cap
  • KELYA 403.0M
  • CAPR 600.7M
  • IPO Year
  • KELYA N/A
  • CAPR N/A
  • Fundamental
  • Price
  • KELYA $12.38
  • CAPR $6.71
  • Analyst Decision
  • KELYA Buy
  • CAPR Strong Buy
  • Analyst Count
  • KELYA 1
  • CAPR 7
  • Target Price
  • KELYA $25.00
  • CAPR $39.29
  • AVG Volume (30 Days)
  • KELYA 249.3K
  • CAPR 2.0M
  • Earning Date
  • KELYA 05-08-2025
  • CAPR 05-13-2025
  • Dividend Yield
  • KELYA 2.46%
  • CAPR N/A
  • EPS Growth
  • KELYA N/A
  • CAPR N/A
  • EPS
  • KELYA N/A
  • CAPR N/A
  • Revenue
  • KELYA $4,451,600,000.00
  • CAPR $22,270,465.00
  • Revenue This Year
  • KELYA $9.54
  • CAPR $78.85
  • Revenue Next Year
  • KELYA $3.92
  • CAPR $157.99
  • P/E Ratio
  • KELYA N/A
  • CAPR N/A
  • Revenue Growth
  • KELYA N/A
  • CAPR N/A
  • 52 Week Low
  • KELYA $10.80
  • CAPR $3.52
  • 52 Week High
  • KELYA $23.85
  • CAPR $23.40
  • Technical
  • Relative Strength Index (RSI)
  • KELYA 61.41
  • CAPR 29.38
  • Support Level
  • KELYA $10.92
  • CAPR $6.57
  • Resistance Level
  • KELYA $11.80
  • CAPR $13.22
  • Average True Range (ATR)
  • KELYA 0.40
  • CAPR 1.19
  • MACD
  • KELYA 0.18
  • CAPR -0.60
  • Stochastic Oscillator
  • KELYA 97.59
  • CAPR 5.46

About KELYA Kelly Services Inc.

Kelly Services Inc is a provider of workforce solutions and consulting, and staffing services. The company's operations are divided into four business segments, namely Professional & Industrial, Science, Education, Outsourcing & Consulting Group, and International. Other than OCG, each segment delivers talent through staffing services, permanent placement, or outcome-based services. OCG segment delivers talent solutions, including managed service providers, payroll process outsourcing, recruitment process outsourcing, and talent advisory services. International also delivers RPO talent solutions within its local markets. The majority of revenue is derived from Professional & Industrial.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: